Baidu
map

Nat Commun:全面总结2型糖尿病基因组分析!

2018-07-31 Michael,Zoe 转化医学网

2型糖尿病(T2D)是人类非常常见的疾病。研究人员对全基因组关联研究(GWAS)进行了Meta-分析,在62,892例T2D病例和596,424例欧洲对照中存在约1600万个遗传变异。他们明确了与T2D相关的139种常见和4种罕见变体,其中42种(39种常见变异体和3种罕见变体)在先前的研究中并未发现。来自血液的基因表达数据与GWAS的结果整合明确了T2D的33个功能基因,其中3个可被批准的药物靶

2型糖尿病(T2D)是人类非常常见的疾病。研究人员对全基因组关联研究(GWAS)进行了Meta-分析,在62,892例T2D病例和596,424例欧洲对照中存在约1600万个遗传变异。他们明确了与T2D相关的139种常见和4种罕见变体,其中42种(39种常见变异体和3种罕见变体)在先前的研究中并未发现。来自血液的基因表达数据与GWAS的结果整合明确了T2D的33个功能基因,其中3个可被批准的药物靶向。该研究的最新成果发表于7月27日的《Nature Communications》。

2型糖尿病目前流行病及基因组研究现状

2型糖尿病(T2D)是一种常见疾病,其全球患病率从1980年的4.7%迅速增加到2014年的8.5%。它主要由胰岛素抵抗和或胰岛素分泌不足引起 。 使用连锁分析和候选基因方法的遗传研究已经发现了一组初始的T2D相关基因座。

在过去十年中,随着样本量的增加,全基因组关联研究(GWAS)在与T2D5,6相关的129个基因座中鉴定出144种遗传变异(不完全独立)。

尽管GWAS明确了大量T2D相关性基因变异,但相关的变异总体上只解释了T2D遗传性的一小部分(大约仅占10%)。这个众所周知的“缺失遗传性”问题可能是存在常见变异的原因,这些变异具有较小的遗传效应但并未被检测出。

罕见变异对常见疾病发生中遗传变异的遗传效应大小目前处于争论阶段,最近的一项研究表明罕见变异对T2D遗传性的贡献有限。此外,在理解GWAS确定的遗传基因座的调控机制方面取得了有限的进展。因此,这种疾病发展病因和遗传基础在很大程度上仍然有待挖掘。

最新全基因组分析结果——T2D研究新纪元

研究者在该Meta-分析中明确了139个常见变异和4个罕见T2D相关性变异。在139个常见基因座中包括了39个先前从未发现的T2D相关性变异。遗憾的是,研究者并没有在UKB发现性别及年龄差异性。

通过整合组学数据,研究者推断出了3种基因(CAMK1D,TP53INP1和ATP5G1)的遗传机制,该机制表明增强子 - 启动子与DNA甲基化的相互作用在介导遗传变异对T2D的影响中起重要作用。

这些发现为T2D的病因学提供了更深入的见解,并提出了未来功能研究的候选基因。此外,研究者表明T2D是一种多基因性状疾病,稀有和常见变异都有助于遗传变异,值得注意的是,稀有变异对T2D产生较大影响。

然而这项研究也存在许多局限性。首先,通过Meta-分析确定的SNP-T2D关联可能因成人的T1D(1型糖尿病)和潜伏性自身免疫性糖尿病的误诊而存在偏倚。其次,一些与T2D相关的SNP可能通过肥胖或血脂异常等介质赋予T2D风险。

此外,胰岛仅构成整个胰腺体积的1-2%,之前的研究揭示了T2D的胰岛特异性基因活性。因此,在使用GTExpancreas数据的SMR分析中,可能遗漏具有胰岛特异性转录或eQTL效应的基因。

尽管存在这些局限性,该研究强调了整合多个组学数据以识别功能基因和由局部遗传变异驱动的推定调控机制的益处。综合组学数据分析的未来应用有望提高医学界对T2D及其他常见疾病的理解。

参考文献:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883218, encodeId=d62f18832180a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 03 04:23:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736149, encodeId=f1a21e361495e, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon Jun 03 14:23:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087392, encodeId=f0b3208e39216, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 10 14:23:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041743, encodeId=72c01041e43f2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 31 14:23:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335318, encodeId=9af73353189d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jul 31 12:27:28 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
    2018-10-03 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883218, encodeId=d62f18832180a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 03 04:23:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736149, encodeId=f1a21e361495e, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon Jun 03 14:23:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087392, encodeId=f0b3208e39216, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 10 14:23:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041743, encodeId=72c01041e43f2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 31 14:23:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335318, encodeId=9af73353189d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jul 31 12:27:28 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883218, encodeId=d62f18832180a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 03 04:23:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736149, encodeId=f1a21e361495e, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon Jun 03 14:23:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087392, encodeId=f0b3208e39216, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 10 14:23:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041743, encodeId=72c01041e43f2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 31 14:23:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335318, encodeId=9af73353189d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jul 31 12:27:28 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
    2019-01-10 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883218, encodeId=d62f18832180a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 03 04:23:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736149, encodeId=f1a21e361495e, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon Jun 03 14:23:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087392, encodeId=f0b3208e39216, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 10 14:23:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041743, encodeId=72c01041e43f2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 31 14:23:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335318, encodeId=9af73353189d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jul 31 12:27:28 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
    2018-07-31 misszhang

    谢谢MedSci提供最新的资讯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1883218, encodeId=d62f18832180a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 03 04:23:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736149, encodeId=f1a21e361495e, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon Jun 03 14:23:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087392, encodeId=f0b3208e39216, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 10 14:23:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041743, encodeId=72c01041e43f2, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 31 14:23:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335318, encodeId=9af73353189d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jul 31 12:27:28 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
    2018-07-31 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

J Periodontol: 2型糖尿病和吸烟对种植体周围炎的影响

本研究旨在评估患不患2型糖尿病(T2DM)的水烟吸烟者(WS)和不吸烟者(NS)种植体周围软组织炎参数和牙槽骨损失(CBL)情况。

健康肥胖”可能不增加2型糖尿病风险

诸多研究证实了肥胖是2型糖尿病(T2DM)的危险因素,然而有趣的是,并不是所有肥胖者的T2DM风险都会升高。近期中国一项研究表明,白细胞(WBC)计数可作为判断肥胖是否会导致T2DM风险增加的指标。那么,为什么选择WBC计数?如何通过WBC计数预测肥胖对于T2DM风险的影响?如何解释WBC计数与T2DM风险的相关性?这一发现有什么临床意义?下面我们将对这些问题进行逐一探讨。

BMJ:治疗2型糖尿病,二甲双胍与磺脲类药物联用比单独用药更安全

发表在《英国医学杂志》上的一项研究发现,对于2型糖尿病患者来说,使用磺酰脲类药物来控制血糖水平与使用二甲双胍相比,会增加并发症的风险。

JCEM:尿三羧酸循环代谢物预测2型糖尿病患者慢性肾病进展

由此可见,关键的TCA循环代谢物,尤其是富马酸,可能参与了T2DM患者CKD进展而不依赖于传统心肾危险因素的病理生理学途径。

Diabetes:选择性Epac激动剂可恢复2型糖尿病胰岛的葡萄糖诱导的Cdc42-Pak1激活和胰岛素分泌

葡萄糖代谢刺激胰腺β细胞的Cdc42-Pak1活动、启动F-肌动蛋白细胞骨架重塑,进而将胞质内的分泌颗粒转运至细胞膜,完成胰岛素外分泌。在β细胞中,葡萄糖代谢还可生成cAMP,cAMP信号与Cdc42-Pak1激活交联可能是葡萄糖刺激胰岛素分泌(GSIS)的基础。既往已明确cAMP调节的鸟嘌呤核氨酸交换因子Epac2可通过cAMP升高剂介导增强GSIS。近期,Rajakrishnan Veluth

JACC:SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险?

使用口服抗凝药(OACs)进行卒中预防是房颤管理的基础。然而,年龄≥90岁的患者使用OACs的数据有限。2018年7月,发表于《Circulation》上的一项队列研究,考察了OACs对老老年房颤(AF)患者的影响。

Baidu
map
Baidu
map
Baidu
map